<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21616">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01798212</url>
  </required_header>
  <id_info>
    <org_study_id>PlicatorLinz</org_study_id>
    <nct_id>NCT01798212</nct_id>
  </id_info>
  <brief_title>Prospective Trial on the Clinical Feasibility of a New Full Thickness Endoscopic Plication Device for Patients With GERD.</brief_title>
  <official_title>A Prospective Multi Center Case Controlled Trial on the Clinical Feasibility of a New Full Thickness Endoscopic Plication Device for Patients With GERD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Barmherzige Schwestern Linz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>General Public Hospital Zell am See</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Krankenhaus Barmherzige Schwestern Linz</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective multi center case controlled trial on the clinical feasibility of a new full
      thickness endoscopic plication device for patients with GERD.

      The primary objective of the present trial is to investigate, clinical feasibility of the
      GERDx™ device, evaluating surgical aspects, quality of life, and symptom sores. Secondary
      objective of the trail is to evaluate objective data before and after the procedure, using
      manometry and 24h impedeance measurement
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Quality of Life using the Gastrointestinal Quality of Life Index</measure>
    <time_frame>change from baseline in Quality of Life  at  3 months, one year and three years after the intervation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>lower esophageal sphincter pressure using oesophageal manometry</measure>
    <time_frame>change from  baseline in lower esophageal sphincter pressure at 3 months, one year and 3 years after the intervantion</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DeMeester score, number of reflux events using 24h-ph-Impedancemeasurment</measure>
    <time_frame>change from  baseline in DeMeester score at 3 months, one year and 3 years after the intervantion</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>full thickness gastroplication</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic full thickness plication</intervention_name>
    <arm_group_label>full thickness gastroplication</arm_group_label>
    <other_name>GERDx™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Written informed consent; ≥ 18 years of age;

        GERD documented by 24h ambulatory Multichannel Impedance-pH-Monitoring off antisecretory
        therapy and/or Gastroscopy by one or more of the following criteria:

          -  Total Number of Reflux Events ≥ 73/24h;

          -  DeMeester Score ≥ 14.7;

          -  Positive Symptom Index - SI ≥ 50% for Symptoms troublesome for the Patient with a
             Frequency of at least 3/24hrs; Macroendoscopically distinct mucosal breaks.

        Exclusion Criteria:

        Patients with known immunological dysfunction (advanced liver disease, HIV, hepatitis C
        virus infection), drug addiction;

        ≤ 18 years of age; Pregnancy and lactation; Previous extensive abdominal surgery; Previous
        esophageal or gastric surgery; Hiatal hernia &gt;2cm; paraesophageal hernia; American Society
        of Anaesthesiologists physical status classification &gt;II
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Schwestern</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver O. Koch, MD</last_name>
      <phone>004373276777300</phone>
      <email>oliverowen.koch@bhs.at</email>
    </contact>
    <investigator>
      <last_name>Oliver O. Koch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georg Spaun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Zell am See</name>
      <address>
        <city>Zell am See</city>
        <zip>5700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolph Pointner, MD</last_name>
      <phone>004365427772010</phone>
    </contact>
    <contact_backup>
      <last_name>Rudolph Pointner, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Rudolph Pointner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 22, 2013</lastchanged_date>
  <firstreceived_date>February 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GERD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
